Categories: NewsPharmaceutical

BBS-Bioactive Bone Substitutes Plc: Managers’ Transactions – Oili Halonen

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

BBS-Bioactive Bone Substitutes Plc, Company announcement, Management transactions, 8 December 2023 at 3.30 p.m. (EET)

BBS-Bioactive Bone Substitutes Oyj – Managers’ Transactions – Oili Halonen

____________________________________________

Person subject to the notification requirement
Name: Halonen Oili
Position: Closely associated person
(1):Person Discharging Managerial Responsibilities In Issuer
Name: Halonen Jarmo
Position: Member of the Board
Issuer: BBS Bioactive Bone Substitutes Oyj
LEI: 743700BYSBP0PCR6N767
Notification type: INITIAL NOTIFICATION
Reference number: 743700BYSBP0PCR6N767_20231208124156_4

____________________________________________

Transaction date: 2023-12-07
Venue not applicable
Instrument type: SHARE
ISIN: FI4000260583
Nature of the transaction: SUBSCRIPTION

Transaction details
(1): Volume: 2,475 Unit price: 0.4 EUR

Aggregated transactions
(1): Volume: 2,475 Volume weighted average price: 0.4 EUR

For more information, please contact:

Juliusz Rakowski, CEO
+358 50 448 5132
juliusz.rakowski@bbs-artebone.fi

Certified Advisor:
Nordic Certified Adviser AB,
+46 70 551 67 29,
info@certifiedadviser.se

BBS in brief

BBS -Bioactive Bone Substitutes Plc is a orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company’s headquarters are in Oulu, and we employ over 20 people.

BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.

More information: www.bbs-artebone.fi

Staff

Recent Posts

Semler Scientific® Appoints Joe Burnett as Director of Bitcoin Strategy; Targets Owning at Least 10,000 Bitcoins by Year-End 2025 and 105,000 by Year-End 2027

CAMPBELL, Calif., June 19, 2025 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a publicly traded…

2 hours ago

The Department of Health – Abu Dhabi and Abbot Unite to Manufacture Pharmaceuticals Locally in Abu Dhabi

Reinforcing Abu Dhabi's position as a global life science hub ABU DHABI, UAE, June 19,…

2 hours ago

ACI Infotech Accelerates Growth with Exclusive Salesforce-Agentforce Partnership and Bold Vision for the Future

SOMERSET, N.J., June 19, 2025 /PRNewswire/ -- ACI Infotech, a tech consulting powerhouse with deep AI,…

2 hours ago

Bridge joins the Elation Health Partner Hub to Elevate Patient Engagement for Elation EHR Users

The award-winning BridgeInteract patient engagement platform gives Elation customers a turnkey suite of self-service tools…

2 hours ago